2Seventy Bio Inc
NASDAQ:TSVT
2Seventy Bio Inc
NASDAQ:TSVT
Price:
5
USD
Market Cap:
$266.2m
Relative Value
The Relative Value of one
TSVT
stock under the Base Case scenario is
2.59
USD.
Compared to the current market price of 5 USD,
2Seventy Bio Inc
is
Overvalued by 48%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
TSVT
Relative Value
Base Case
2.59
USD
Overvaluation 48%
Multiples Across Competitors
TSVT Competitors Multiples
2Seventy Bio Inc Competitors
2Seventy Bio Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
2Seventy Bio Inc
NASDAQ:TSVT
|
257.9m USD | 6.8 | -4.5 | -0.9 | -0.8 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 643 258.8 | -159 901.4 | -194 171.3 | -191 955.6 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
387.4B USD | 6.5 | 166 | 16.1 | 22.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
201.5B USD | 5.5 | 26 | 14.9 | 14.9 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
186.3B USD | 6.4 | 23 | 15.6 | 15.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
117.8B USD | 10.1 | 32.1 | 23.6 | 24.6 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 094 | -534.3 | -581.8 | -566.3 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
80.5B USD | 5.7 | 18 | 15.3 | 17.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
87.1B AUD | 3.9 | 20.2 | 13.5 | 16.8 | |
| NL |
|
argenx SE
XBRU:ARGX
|
41.9B EUR | 14.2 | 33.3 | 56.8 | 58.4 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.2 | -61.8 | -66.7 | -60.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
